The massive capital raise (equity + convertible) is a large, certain present dilution event. The concurrent convertible note offering adds ~$500M debt with a conversion premium of ~34% above the offering price, creating future dilution overhang. The stock is likely to trade down as the market absorbs the new supply and the dilution from the convertible notes. Monitor the stock's price relative to the conversion price (~$89.60) for potential hedging activity by note arbitrageurs.
Price Chart
Executive Summary
Vaxcyte is raising ~$474M in a common stock and pre-funded warrant offering priced at $64.00/share (4% discount to the $66.70 close), alongside a concurrent $500M convertible note offering. The proceeds will fund clinical development and commercial preparation for its lead pneumococcal vaccine candidate VAX-31, which recently reported positive Phase 3 OPUS-1 topline results. The offering creates immediate and substantial dilution of $43.49/share for new investors and adds significant future dilution risk from the convertible notes and potential future equity sales.
Key Facts
- Offering of 7,412,500 shares of common stock and pre-funded warrants to purchase 400,000 shares at $64.00/share (public offering price), raising ~$473.3M in net proceeds (or ~$544.3M if underwriters' option to purchase an additional 1,171,875 shares is exercised in full).
- Concurrent convertible note offering of $500M aggregate principal amount of 1.50% convertible senior notes due 2032, with an initial conversion price of ~$89.60/share, adding ~$485.8M net proceeds (or ~$558.7M with full over-allotment).
- Last reported sale price on October 6, 2026 was $66.70/share; offering priced at a ~4% discount.
- Immediate dilution of $43.49 per share to new investors based on as-adjusted net tangible book value of $20.51/share post-offering.
- Proceeds intended to fund VAX-31 adult Phase 3 program (OPUS-2, OPUS-3, manufacturing consistency study), VAX-31 infant Phase 2 study, manufacturing scale-up, commercial launch preparation, and other pipeline R&D.
- VAX-31 Phase 3 OPUS-1 trial met all prespecified co-primary immunogenicity endpoints in adults 50+; serotypes 3 and 12F missed noninferiority vs PCV21 but met historical threshold.
- Cash, cash equivalents and investments expected to be ~$2.3B as of September 30, 2026.
- Underwriters have a 30-day option to purchase up to an additional 1,171,875 shares of common stock.
- Executive officers and directors subject to 60-day lock-up agreements.
Financial Impact
~$473.3M net proceeds from this offering (plus up to ~$544.3M with full option exercise); ~$485.8M net from concurrent convertible note offering (up to ~$558.7M with full over-allotment). Total potential combined gross proceeds up to ~$1.1B.
Risk Factors
- Immediate and substantial dilution of $43.49/share for new investors
- Future dilution from potential exercise of pre-funded warrants, options, RSUs, and conversion of convertible notes
- Potential future dilution from potential future equity sales under the $500M at-the-market program (no sales for 30 days)
- Potential future dilution from convertible note arbitrage hedging activity that could depress stock price
- Management has broad discretion over use of proceeds; no specific commitments for acquisitions or investments
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-417977 |
| Document: d176371dexfilingfees.htm | 0001193125-26-417977 |
| Document: 0001193125-26-417977-index-headers.html | 0001193125-26-417977 |
| Document: 0001193125-26-417977-index.html | 0001193125-26-417977 |
| Document: 0001193125-26-417977.txt | 0001193125-26-417977 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $70.65 $63.68 | ▲ +9.87% | ▲ +8.37% | $60.67 (+14.13%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▲ +0.15% | ▲ +0.29% | $60.67 (−9.04%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▼ −0.15% | ▼ −0.29% | $60.67 (+9.04%) |
Oct 5, 2026 22d ago | 8-K | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 5, 2026 22d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 4, 2026 23d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Aug 5, 2026 11w ago | Insider Cluster | $58.89 $58.86 | ▼ −0.05% | ▼ −1.26% | $60.67 (+3.02%) |
Jul 6, 2026 16w ago | Insider Cluster | $60.67 $56.21 | ▼ −7.35% | ▼ −7.90% | $60.67 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers